Nie stanowi porady lekarskiej, reklamy produktu leczniczego ani rekomendacji terapeutycznej
When available, review the current COA, HPLC chromatogram, and MS document
GLP-1 stimulates insulin production, thus reducing blood glucose levels, and it interacts with the brain to suppress appetite and create a feeling of fullness
For 10 days, healthy subjects received 10 mg of oral semaglutide (formulation R1) once daily doses with 50 mL or 120 mL of water under fasting conditions with post-dose fasting period of 15, 30, 60 or 120 minutes
[2] Heres what we know about side effects from the STEP UP clinical trial so far: Around 1 in 3 patients taking Wegovy 7.2 mg experienced nausea Around 1 in 6 patients experienced diarrhoea Around 1 in 6 patients experienced vomiting Around 1 in 7 patients experienced constipation A side effect called 'dysaesthesia' was also noted in the STEP UP trial, occurring in nearly 1 in 4 of participants taking Wegovy 7.2 mg